Abstract:Detection of NSCLC at the early stage is a potential means to reduce mortality and morbidity of lung cancer. Development of an accurate, non-invasive, economical, and safe test to detect early stage NSCLC remains a challenge. We explored metabolomics profiling of plasma to discriminate early stage NSCLC cases from Cancer-Free Controls (CFC). Frozen plasma samples collected from 2004 to 2014 from 250 patients with clinical early stage NSCLC (drawn prior to surgical resection) and 250 CFCs were obtained from a provincial biorepository. Samples were thawed, extracted, and analyzed in duplicate by blinded laboratory personnel using non-targeted Ultra High Performance Liquid Chromatography/Quadrupole Time-Of-Flight Mass Spectrometry (UHPLC-QTOF-MS). Individual metabolic entities were identified and quantified using Mass Profiler Professional Software (Agilent Technologies, CA, USA). Analysis was restricted to known human metabolites identified by the Metlin and Human Metabolome databases. Candidate metabolites quantified in less than 20% of samples were dropped; missing values were replaced with one-half of the smallest measurement for each metabolite. Final candidate metabolites were screened for differential abundance (DA) between NSCLC cases and CFCs using: (1) False discovery rate (FDR)-adjusted p-values less than 1% after controlling for age, sex and smoking status in linear regression; (2) <1% change in DA due to covariates; (3) up-regulation in NSCLC. Of the 250 NSCLC Cases, 185 (74%) had adenocarcinoma, 65 (26%) had Squamous Cell Carcinoma; 204 (81.6%) had pathological Stage I/II disease (AJCC 7th ed) and 46 (18.4%) had stage III/IV disease. Median age was 70 (range 46-88) in NSCLC cases and 56 (20-89) in CFCs (p<0.001), and NSCLC cases had more males compared to CFCs (46.4% vs 31.2%, p <0.001). NSCLC patients had a higher proportion of current (27.2% vs 6%) or ex-smokers (64.8% vs 20.8%) compared to CFCs (p<0.001). A total of 1,209 known human metabolites were detected using UHPLC-QTOF-MS technique, of which 676 were present in a minimum of 80% of all samples and were used for modeling. Table 1 lists candidate metabolomics biomarkers strongly upregulated in NSCLC cases versus CFCs which were unaffected by covariates of age, sex, and smoking. A multiple logistic regression model using the top 3 metabolites correctly classified NSCLC case from CFC with an overall accuracy of 93.6% and an area under the curve of 0.975. Metabolomics profiling of plasma represents a potential means to distinguish NSCLC cases from CFCs. Further targeted metabolomics analyses of specific classes of metabolites in larger cohorts are warranted.

Clinical Validation of Metabolite Markers for Early Lung Cancer Detection

P2.11-10 Discovery of Potential Biomarkers That Discriminate Early Stage NSCLC from Controls by Non-Targeted Metabolomics Profiling

Cortisol, Cortisone, and 4-Methoxyphenylacetic Acid As Potential Plasma Biomarkers for Early Detection of Non-Small Cell Lung Cancer

Serum Untargeted Metabolomics Reveal Metabolic Alteration of Non‐small Cell Lung Cancer and Refine Disease Detection

Serum Untargeted Metabolomics Analyses Reveal Metabolic Alteration of Non-Small Cell Lung Cancer and Refine Cancer Detection in Chinese Population

High-resolution metabolomic biomarkers for lung cancer diagnosis and prognosis

Plasma Metabolomics for the Assessment of the Progression of Non-Small Cell Lung Cancer

Integrated Models of Blood Protein and Metabolite Enhance the Diagnostic Accuracy for Non-Small Cell Lung Cancer

Detection and Verification of Coexisting Diagnostic Markers in Plasma and Serum of Patients with Non-Small-cell Lung Cancer

Application of Metabolomics by UHPLC-MS/MS in Diagnostics and Biomarker Discovery of Non-Small Cell Lung Cancer

Screening and Identification of Potential Novel Lipid Biomarkers for Non‐small Cell Lung Cancer Using Ultra‐high Performance Liquid Chromatography Tandem Mass Spectrometry

Early lung cancer diagnostic biomarker discovery by machine learning methods

Metabolic Network-Based Identification of Plasma Markers for Non-Small Cell Lung Cancer

Metabolite Profiles of the Serum of Patients with Non–Small Cell Carcinoma

Diagnosing lung cancer through metabolic fingerprint based on machine learning

A comprehensive analysis of metabolomics and transcriptomics in non-small cell lung cancer

High-Throughput Salivary Metabolite Profiling on an Ultralow Noise Tip-Enhanced Laser Desorption Ionization Mass Spectrometry Platform for Noninvasive Diagnosis of Early Lung Cancer.

Ultrasensitive DNA Hypermethylation Detection Using Plasma for Early Detection of NSCLC: A Validation Study in Chinese Patients.

Molecular biomarkers in early stage lung cancer

Lung cancer scRNA-seq and lipidomics reveal aberrant lipid metabolism for early-stage diagnosis

Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms